Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes-Reference-Cited by-同舟云学术

Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes

Published:2024-05-21 Issue:5 Volume:2024 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Natale Patrizia¹²³,Tunnicliffe David J¹⁴,Toyama Tadashi⁵⁶,Palmer Suetonia C⁷,Saglimbene Valeria M¹³,Ruospo Marinella¹³,Gargano Letizia³,Stallone Giovanni⁸,Gesualdo Loreto³,Strippoli Giovanni FM¹³⁹

Affiliation:

1. Sydney School of Public Health; The University of Sydney; Sydney Australia

2. Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy

3. Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J) Nephrology, Dialysis and Transplantation Unit; University of Bari Aldo Moro; Bari Italy

4. Centre for Kidney Research; The Children’s Hospital at Westmead; Westmead Australia

5. Department of Nephrology; Kanazawa University; Kanazawa Japan

6. Innovative Clinical Research Center; Kanazawa University; Kanazawa Japan

7. Department of Medicine; University of Otago Christchurch; Christchurch New Zealand

8. Nephrology, Dialysis and Transplantation Unit; Department of Medical and Surgical Sciences, University of Foggia; Foggia Italy

9. Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia

Publisher

Wiley

Reference409 articles.

1. Safety and effectiveness of bexagliflozin in type 2 diabetes mellitus and stage 3a/3b CKD: a phase 3 randomized clinical trial [abstract no: FR-OR144];Allegretti;Journal of the American Society of Nephrology,2018

2. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD;Allegretti;American Journal of Kidney Diseases,2019

3. Improved cardiovascular and renal outcomes in the canagliflozin cardiovascular assessment study (CANVAS) program irrespective of baseline (BL) body mass index (BMI) [abstract no: 1206-P];Bays;Diabetes,2018

4. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus;Figtree;Circulation,2019

5. How does canagliflozin confer renoprotection? Results from a mediation analysis of the CANVAS program [abstract no: FR-PO232];Li;Journal of the American Society of Nephrology,2019